Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Theratome Bio General Information
Theratome Bio has developed a proprietary secretome-based therapeutic platform derived from adult stem cells. Its lead product, Thera‑101, is an injectable biologic targeting ischemic brain injury with first-in-human trials underway. The company’s technology also aims to double the shelf life of transplanted organs and address dry eye disease. Preclinical data support tissue-protective and regenerative effects across multiple indications.[1][4]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Indianapolis* / Florida*, Indiana / Florida*
United States
United States
Drug Pipeline
KM102
Pre-clinicalKey Partnerships
No major pharmaceutical partnerships disclosed as of May 2025., Spring Mill Venture Partners listed as an investor.[3]
Theratome Bio Funding
No funding data available
To view Theratome Bio's complete valuation and funding history, request access »